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Summary Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of
action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies
have shown significant anti-tumour effects in animal models. We performed a phase II study in previously
untreated patients with advanced colorectal cancer, using a schedule of i.v. bolus infusions of 900 Mg m 2 once
every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients.
Toxicity mainly consisted of a highly selective neutropenia, which warrants further investigation of this agent in
combination with myeloid growth factors.
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Tallimustine is a synthetic derivative of the antiviral
distamycin A, in which a formyl group at the N-terminal
position has been replaced by an alkylating benzoyl mustard
moiety (Arcamone et al., 1989). Although its mechanism of
action is not precisely known, its anti-tumour activity has
been attributed to a very limited number of highly sequence-
specific alkylations of DNA (Broggini et al., 1995).
Tallimustine binds preferentially to adenine-thymine rich
sequences in the minor groove of DNA, inhibits the binding
of transcription factors that recognise these sequences and
specifically inhibits DNA ligase. Unlike classic alkylating
agents it does not alkylate guanine N7 but only adenine N3
(Broggini et al., 1991; Coley et al., 1993, Montecucco et al.,
1991). Furthermore, it has immunomodulating properties in
that it augments T-cell-dependent antibody production
(Riganti et al., 1992). It displays potent anti-tumour effects
on human and murine tumour cell lines as well as on murine
transplated solid tumours and human tumour xenografts
(Arcamone et al., 1989; Giuliani et al., 1988; Pezzoni et al.,
1991). Tallimustine is cross-resistant with doxorubicin but
not with melphalan and cisplatin, and drug resistance is only
partially mediated through mdr-J-p170 (Pezzoni et al., 1991;
Geroni et al., 1993; Capolongo et al., 1993). The dose-
limiting toxicity in phase I studies was a highly selective
neutropenia (Sessa et al., 1994; Abigerges et al., 1993;
Hageboutros et al., 1994). In these studies clinical responses
were documented in mesothelioma, ethmoid adenocarcinoma
and ovarian cystadenocarcinoma. Given the paucity of active
agents in patients with advanced colorectal cancer, we
initiated a phase II study in previously untreated patients
to determine the anti-tumour activity of this new agent.
Patients and methods
Inclusion criteria included histologically documented unre-
sectable advanced or metastatic colorectal cancer, no prior
systemic treatment with the exception of adjuvant chemother-
apy more than 12 months prior to entry, measurable disease
parameter(s), no prior radiotherapy on all disease para-
meters, age > 18 and <70 years, ECOG performance status
,<2, life expectancy >3 months, WBC >4 x 109l 1,
granulocytes >2 x 109-' 1, platelets >100 x 109-' 1, serum
bilirubin < 1.5 mg dl-1, alkaline phosphatase, ASAT, and
ALAT <2 x upper limit of normal (in case of liver
metastases <5 x), no signs of brain metastases, no active
infections, no second malignancy (with the exception of
adequately treated in situ carcinoma of the cervix or
squamous cell carcinoma of the skin), no pregnant or
breastfeeding women, and written or oral witnessed
informed consent.
Tallimustine (FCE 24517, Pharmacia, Milan, Italy) was
administered at 900 jug m-2 as an i.v. bolus infusion over 3-
5 min, once every 4 weeks. Patients were followed weekly for
toxicity and every two cycles for response. Full blood counts
were determined weekly and twice weekly in the third week of
treatment. Toxicity and response were evaluted according to
CTC and WHO criteria respectively. Treatment was only
continued after 4 weeks when neutrophil and platelet counts
were normal (grade 0). When treatment was postponed or, in
the case of neutrophil nadir grade 4 for >7 days or <7 days
but accompanied by fever > 38.50C, the dose in the
subsequent cycle was reduced by 25%. The use of colony-
stimulating factors was prohibited. No anti-emetic prophy-
laxis was given during the first cycle, but was allowed in
following cycles when clinically indicated. Patients with
progressive disease after two cycles were taken off study,
and patients with stable disease received a minimum of four
cycles. A two-stage design of the study was used in order to
permit termination of the study when no responses were
documented in the first group of 14 patients.
Results
Seventeen patients were entered into the study. Patient
characteristics are shown in Table I. Patients received a
median of two (1-4) cycles, the total number of administered
cycles was 34. Three patients were not evaluable for response:
one patient refused further treatment after one cycle, one
patient was taken off study after one cycle as a result of the
development of a pelvic abscess and fistulae, one patient died
after the second cycle before tumour evaluation had been
performed. Of the 14 patients who were evaluable for
response, 13 had progressive disease after a median of two
(1-4) cycles, and one patient with stable disease after two
cycles refused further treatment (total response rate 0%, 95%
confidence interval 0-23%). Toxicity mainly consisted of
neutropenia (Table II). A total of 13 (76%) patients
experienced grade III/IV leucocytopenia and/or neutropenia
during 21 (62%) cycles. Three patients developed febrile
episodes during neutropenia that resulted in hospital
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Table I Patients' characteristics
Male/female 13/4
Median age (years) (range) 58 (43-66)
Median ECOG performance status (range) 1 (0-2)
Localisation of primary tumour
Colon 9
Rectosigmoid 2
Rectum 6
Localisation of metastatic disease
Liver 12
Lung 2
Lymph nodes 4
Local recurrence 2
Other 6
Median number of metastatic sites 1 (1-3)
Previous treatments
Surgery 16
Radiotherapy 4
Adjuvant chemotherapy I
None 1
Numbers are patients.
admissions for treatment with i.v. antibiotics. Grade IV
neutropenia occurred between days 13 and 17 after the start
of treatment and had a median duration of 4 (range 2-9)
days. Of the 14 patients who received at least two cycles,
toxicity-related dose reductions and treatment delays were
performed in one (7%) and two (14%) patients respectively.
In these 14 patients no cumulative effect on bone marrow
toxicity was seen. Platelet toxicity occurred in only one
patient (grade 2). One patient developed symptoms of arterial
insufficiency of the left leg together with hypotension and
anuria 13 days after the second administration of tallimus-
tine. He also had afebrile grade IV neutropenia, which lasted
only 2 days. Despite vigourous treatment with anticoagu-
lants, pressor agents and i.v. antibiotics he died 11 days later
as a result of thromboembolic complications resulting in
multiorgan failure, confirmed by autopsy. A relation with
tallimustine was thought unlikely.
Table I Toxicity of treatment
Grade
Toxicity II III IV
Leucocytopenia 4 6 4
Neutropenia I 1 12
Thrombocytopenia 1 0 0
Anaemia 4 2 0
Infection 0 0 3
Nausea' 1 2 0
Vomiting 2 1 0
Anorexia 2 2 0
Diarrhoea 1 1 0
Fatigue 1 2 0
Numbers are patients, maximum toxicity per patient is given.
Toxicity according to CTCcriteria. aNo prophylacticantiemetics were
administered during the first cycle.
Tallimustine appears to be an attractive cytotoxic agent
because of its unique mechanism of action, its potent
preclinical anti-tumour activity in vitro and in vivo and its
lack of non-haematological toxicity. However, we found no
activity in patients with advanced colorectal cancer. Studies
in other types of cancer are ongoing. Toxicity consisted of a
highly selective neutropenia, which confirms the data
obtained from phase I studies (Sessa et al., 1994; Abigerges
et al., 1993; Hageboutros et al., 1994). A concentration-
dependent inhibition of human myeloid progenitor cells has
been demonstrated (Volpe et al., 1993). The striking absence
ofplatelet toxicity as well as the low incidence ofmanageable
non-haematological toxicities makes this agent a very
attractive candidate for combination with myeloid growth
factors.
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